Endo, Mallinckrodt

Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal
Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued at nearly $7 billion to boost scale for selling their branded drugs. Endo shareholders will get $80 million in cash and own 49.
Mallinckrodt and Endo plan merger as they look to recover from opioid litigation
The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in 2025 and at least $150 million of annual operating synergies by year three.
Mallinckrodt to take over Endo in deal valued at $6.7 billion
Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said Thursday that Endo shareholders will receive a total of $80 million in cash and own nearly 50% of the combined company. Mallinckrodt shareholders will have a stake of slightly more than 50%.
Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger
Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced plans Thursday to join forces in a deal valued at $6.7 billion. Mallinckrodt Chief Executive Siggi Olafsson said the companies' operations and products complement each other.
Mallinckrodt and Endo sign $6.7bn merger deal
The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.
Drugmakers Mallinckrodt and Endo Are in Talks to Merge
Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said.
Mallinckrodt, Endo look to carve out brighter future through $6.7B merger
Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the agreement, Endo shareholders are slated to receive a total of $80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will have a 50.1% piece of the pie.
Mallinckrodt, Endo to combine in $7B deal
The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...
Mallinckrodt and Endo to merge
Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the transaction.
Drugmakers Mallinckrodt, Endo in talks to merge, source says
Mallinckrodt and Endo are exploring a potential merger that could be valued at about $7 billion, person familiar with the matter told Reuters on Wednesday.
Mallinckrodt and Endo to combine after emerging from bankruptcy linked to opioid crisis
Mallinckrodt Pharmaceuticals and Endo have agreed to combine in a nearly $7bn deal after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis.
The Mercury3d
Chester County-based Endo to be sold for $6.7 billion
EAST WHITELAND — Endo, a pharmaceutical company that has its global headquarters in Chester County, is being acquired by ...
Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader
Mallinckrodt plc ("Mallinckrodt") and Endo, Inc. (OTCQX: NDOI) ("Endo") today announced that they have entered into a definitive agreement to combine in a stock and cash transaction to create a global ...